Last update June 24, 2020
Monoclonal antibody fragment that binds to platelet receptors inhibiting platelet aggregation. Used to treat angioplasty and unstable angina.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data: very high molecular weight, high percentage of platelet binding (Harder 1999) and short half-life, make it very unlikely it will pass into breast milk in significant amounts.
Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed. This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM